# US 2020/0002409 A1 · Compositions and methods for the removal of biofilms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002409 A1
- Document ID: US20200002409A1
- Status: Published application
- Kind: A1
- Application number: 15/999,215
- Filed: 2018-08-16
- Published: 2020-01-02
- Earliest claimed: 2013-06-13
- Assignees: Research Institute At Nationwide Children's Hospital
- Applicants: Research Institute at Nationwide Children's Hospital
- Inventors: Steven D. Goodman; Lauren O. Bakaletz
- Web page: https://patentgrep.com/patent/US20200002409A1

## CPC

- C07K 16/1242: {from Pasteurellaceae (F), e.g. Haemophilus influenza}
- A01N 37/46: N-acyl derivatives
- A01P 1/00: Disinfectants; Antimicrobial compounds or mixtures thereof
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/40: bacterial
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/12: against material from bacteria
- C07K 16/1232: Escherichia (G)
- C07K 16/40: against enzymes
- G01N 33/56911: {Bacteria}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/24: Immunology or allergic disorders
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01P: BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

## Claims

### Claim 1

An isolated polypeptide comprising the amino acid sequence of the Haemophilus influenzae IHFa or a fragment or equivalent thereof; and optionally, wherein the peptide is selected from the group of: the tip portion of the DNABII polypeptide; the A5 fragment of IHFa chain; or a polypeptide consisting of an amino acid sequence selected from the group of an amino acid sequence corresponding to positions 10-25 of the Haemophilus influenzae IHFa chain; an amino acid sequence corresponding to positions 56-78 of the Haemophilus influenzae IHFa; or an amino acid sequence corresponding to positions 86-96 of the Haemophilus influenzae IHFa; or a polypeptide comprises the amino acid sequence selected from the group of TFRPGQKLKSRVENASPKDE (SEQ ID NO: 252), MATITKLDIIEYLSDKYHLS (SEQ ID NO: 348), KYHLSKQDTKNVVENFLEEI (SEQ ID NO: 349), FLEEIRLSLESGQDVKLSGF (SEQ ID NO: 350), KLSGFGNFELRDKSSRPGRN (SEQ ID NO: 351), RPGRNPKTGDVVPVSARRVV (SEQ ID NO: 352), ARRVVTFKPGQKLRARVEKTK (SEQ ID NO: 353), or a biological equivalent each thereof; and optionally wherein the isolated polypeptide further comprises a heterologous amino acid sequence or is coupled to a heterologous non-peptide domain.

### Claim 2 (depends on 1)

A method to obtain antibodies immunoreactive with an IHF protein or to generate B cells that secrete antibodies immunoreactive with an IHF protein, comprising administering the peptide of claim 1 to a subject; and recovering antibodies or recovering B cells from the subject.

### Claim 3 (depends on 2)

The method of claim 2, which further comprises screening the B cells recovered from the subject for secretion of an antibody with high affinity for an IHF protein, thus identifying B cells that secrete antibodies immunoreactive with IHF; and optionally isolating DNA or mRNA encoding said antibodies from said cells.

### Claim 4 (depends on 1)

A method to produce a DNABII polypeptide, comprising culturing mammalian cells that have been modified to contain a polynucleotide or an expression vector for the polypeptide, of claim 1.

### Claim 5 (depends on 1)

A method to prevent formation of or to dissolve a biofilm in a subject in need thereof, comprising administering to the isolated polypeptide of claim 1.

### Claim 6 (depends on 1)

A small molecule that mimics the epitope to which the antibody, the antigen binding fragment, or the interfering agent of claim 1 binds, wherein the epitope is a Staphylococcus aureus DNABII or a fragment thereof; and optionally, wherein the fragment of Staphylococcus aureus DNABII comprises a tip fragment or beta hairpin portion, or a biological equivalent thereof.

### Claim 7 (depends on 6)

A method to obtain antisera effective to dissolve biofilm, comprising immunizing a subject with the small molecule of claim 6, and recovering antiserum from the subject, and optionally isolating polyclonal antiserum or monoclonal antibodies from the subject.

### Claim 8 (depends on 7)

A method to treat biofilm-related conditions in a subject, which method comprises administering to the subject one or more of: the antiserum, the monoclonal antibodies, or the small molecule of claim 7.
